{"id":419956,"date":"2021-01-25T07:03:12","date_gmt":"2021-01-25T12:03:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=419956"},"modified":"2021-01-25T07:03:12","modified_gmt":"2021-01-25T12:03:12","slug":"cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/","title":{"rendered":"Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">\n        <em>Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company\u2019s advancement of therapeutic pipeline candidates<\/em>\n      <\/p>\n<p align=\"left\">CAMBRIDGE, Mass., Jan.  25, 2021  (GLOBE NEWSWIRE) &#8212; Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of clinical and scientific advisory boards comprised of academic leaders with expertise in CNS diseases and the development of novel therapeutics.<\/p>\n<p align=\"left\">\u201cWe are pleased to have assembled an accomplished and diverse group of advisors with expertise that spans clinical development in neurology and translational science, as well as CNS disease biology. The advisors\u2019 expertise will be highly valuable for optimizing the development path and therapeutic potential of the company\u2019s pipeline including CY6463, our first-in-class CNS-penetrant sGC stimulator,\u201d said Andreas Busch, Ph.D., Chief Scientific Officer of Cyclerion.<\/p>\n<p align=\"left\">\u201cI look forward to working closely with our advisors to advance our promising pipeline, starting first with ADv and MELAS and to explore additional indications associated with cognitive impairment,\u201d said\u00a0Christopher Wright, M.D., Chief Medical Officer of Cyclerion.<\/p>\n<p align=\"left\">\n        <strong>Clinical Advisory Board:<\/strong>\n      <\/p>\n<ul>\n<li>\n          <strong><br \/>\n            <a href=\"https:\/\/www.bu.edu\/alzresearch\/profile\/andrew-budson-md\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n              <u>Andrew E. Budson, M.D.<\/u><br \/>\n            <\/a><br \/>\n          <\/strong>: Chief of Cognitive &amp; Behavioral Neurology and Director of the Center for Translational Cognitive Neuroscience at the Veterans Affairs Boston Healthcare System, Associate Director and Education Leader of the Boston University Alzheimer\u2019s Disease Research Center, Professor of Neurology at Boston University School of Medicine, and Lecturer in Neurology at Harvard Medical School\u00a0<\/li>\n<li>\n          <strong><br \/>\n            <a href=\"https:\/\/hbi.ucalgary.ca\/profiles\/dr-eric-smith\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n              <u>Eric Smith, M.D<\/u><br \/>\n            <\/a><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <u>.<\/u><br \/>\n          <\/strong>: Professor of Neurology and the Katthy Taylor Chair in Vascular Dementia at the University of Calgary, Calgary Stroke Program<\/li>\n<li>\n          <strong><br \/>\n            <a href=\"https:\/\/connects.catalyst.harvard.edu\/Profiles\/display\/Person\/84202\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n              <u>M Brandon Westover, M.D., Ph.D<\/u><br \/>\n            <\/a><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <u>.<\/u><br \/>\n          <\/strong><br \/>\n          <strong>:<\/strong>\u00a0Physician Investigator in Neurology at Mass General Research Institute, Associate Professor of Neurology at Harvard Medical School, Associate Neurologist in Neurology at Massachusetts General Hospital, and Co-Founder, Beacon Biosignals<\/li>\n<li>\n          <strong><br \/>\n            <a href=\"https:\/\/www.nmr.mgh.harvard.edu\/user\/5826\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n              <u>David H. Salat, Ph.D.<\/u><br \/>\n            <\/a><br \/>\n          <\/strong>: Director, Brain Aging and Dementia Laboratory, Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital; Associate Professor in Radiology at Harvard Medical School; and Director, Neuroimaging Research for Veterans Center, Veterans Affairs Boston Healthcare System<\/li>\n<\/ul>\n<p>\n        <strong>Scientific Advisory Board:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong><br \/>\n            <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=currie+mg&amp;sort=date&amp;show_snippets=off\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n              <u>Mark Currie, Ph.D<\/u><br \/>\n            <\/a><br \/>\n          <\/strong><br \/>\n          <strong>.<\/strong> (Chair): External Advisor with over 40\u202fyears of experience studying nitric oxide, guanylate\u202fcyclases\u202fand cGMP signaling<\/li>\n<li>\n          <strong><br \/>\n            <a href=\"https:\/\/profiles.stanford.edu\/robert-malenka\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n              <u>Robert C. Malenka, M.D., Ph.D<\/u><br \/>\n              <u>.<\/u><br \/>\n            <\/a><br \/>\n          <\/strong><br \/>\n          <strong>:<\/strong>\u00a0Pritzker Professor of Psychiatry and Behavioral Sciences, Director of the Nancy Pritzker Laboratory, and Deputy Director of the Wu Tsai Neurosciences Institute at Stanford University<\/li>\n<li>\n          <strong><br \/>\n            <a href=\"https:\/\/www.slu.edu\/medicine\/medical-education\/graduate-programs\/pharmacology-physiology\/faculty\/salvemini-daniela.php\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n              <u>Daniela Salvemini, Ph.D<\/u><br \/>\n              <u>.<\/u><br \/>\n            <\/a><br \/>\n          <\/strong><br \/>\n          <strong>:<\/strong>\u00a0Professor of Pharmacology and Physiology and Director of the Henry and Amelia Nasrallah Center for Neuroscience at St. Louis University<\/li>\n<li>\n          <strong><br \/>\n            <a href=\"http:\/\/haraldschmidt.online\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n              <u>Harald H.H.W. Schmidt, M.D., Ph.D., PharmD<\/u><br \/>\n              <u>.<\/u><br \/>\n            <\/a><br \/>\n          <\/strong><br \/>\n          <strong>:<\/strong>\u00a0Professor of Pharmacology and Chairman of the Department of Pharmacology and Personalized Medicine at Maastricht University<\/li>\n<\/ul>\n<p>\n        <strong>About\u00a0Cyclerion Therapeutics\u00a0<\/strong><br \/>\n        <br \/>Cyclerion Therapeutics\u00a0is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion\u2019s lead program is CY6463, a first-in-class, CNS-penetrant, sGC stimulator that modulates a key node in a fundamental CNS signaling network.\u00a0 \u00a0The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. CY6463 has shown rapid improvement in biomarkers associated with cognitive impairment and is currently in clinical development for Alzheimer&#8217;s Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS).<\/p>\n<p>For more information about Cyclerion, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=auISFjObsezfPEA7wnv8wICtDiYtIyDqUBLefGpjgoXMihtKkhlZ03CASNNBayuRItjJft_0tEszl2YQjnwnBL0MwEAbNMhuZ2D9m74GZdM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>https:\/\/www.cyclerion.com\/<\/u><\/a>\u00a0and follow us on Twitter (@Cyclerion) and LinkedIn (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O90ro_IKgiLsPn47WE1fe7CeKCqQVIzyf4AD_uBzvtUHtb6TlCu_BCb4voeiNNo_XfaJJODRJ56-ZMHEVLkJFDhqGzij2uMQxvz_DoXgQND07d5YJQwxgLUNaW3R7s6wdn7HNNEsiAkTTlxVC7_nDQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.linkedin.com\/company\/cyclerion<\/u><\/a>).<\/p>\n<p>\n        <strong>Forward Looking Statement<br \/><\/strong>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. We may, in some cases use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201clikely,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks listed under the heading \u201cRisk Factors\u201d and elsewhere in our 2019 Form 10-K filed on\u00a0March 12, 2020, and in Cyclerion\u2019s subsequent\u00a0SEC\u00a0filings, including the Form 10-Qs filed on\u00a0May 4, 2020,\u00a0August 3, 2020\u00a0and\u00a0November 5, 2020. Investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and Cyclerion undertakes no obligation to update these forward-looking statements, except as required by law.<\/p>\n<p>\n        <strong>Investors<br \/><\/strong>Carlo Tanzi, Ph.D.<br \/>Kendall Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tZc-qYI3VF-ZRN_wGmWmtBCPdS9tCM8KiN65NcJR6e3BaavNyqVfM8FxVPfID6bRAW6fk_BWULQjFcoj-8tYaFbMnJf4jRdlbh7S9PgSu6A=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ctanzi@kendallir.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDY2MSMzOTQyNDM5IzIxMjUwMjQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/80841f21-6e6b-4be7-b045-114bbafdce3d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company\u2019s advancement of therapeutic pipeline candidates CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) &#8212; Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of clinical and scientific advisory boards comprised of academic leaders with expertise in CNS diseases and the development of novel therapeutics. \u201cWe are pleased to have assembled an accomplished and diverse group of advisors with expertise that spans clinical development in neurology and translational science, as well as CNS disease biology. The advisors\u2019 expertise will be highly valuable for optimizing the development path and therapeutic potential of the company\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-419956","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company\u2019s advancement of therapeutic pipeline candidates CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) &#8212; Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of clinical and scientific advisory boards comprised of academic leaders with expertise in CNS diseases and the development of novel therapeutics. \u201cWe are pleased to have assembled an accomplished and diverse group of advisors with expertise that spans clinical development in neurology and translational science, as well as CNS disease biology. The advisors\u2019 expertise will be highly valuable for optimizing the development path and therapeutic potential of the company\u2019s &hellip; Continue reading &quot;Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-25T12:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDY2MSMzOTQyNDM5IzIxMjUwMjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards\",\"datePublished\":\"2021-01-25T12:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\\\/\"},\"wordCount\":791,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDY2MSMzOTQyNDM5IzIxMjUwMjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\\\/\",\"name\":\"Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDY2MSMzOTQyNDM5IzIxMjUwMjQ=\",\"datePublished\":\"2021-01-25T12:03:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDY2MSMzOTQyNDM5IzIxMjUwMjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDY2MSMzOTQyNDM5IzIxMjUwMjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/","og_locale":"en_US","og_type":"article","og_title":"Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards - Market Newsdesk","og_description":"Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company\u2019s advancement of therapeutic pipeline candidates CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) &#8212; Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of clinical and scientific advisory boards comprised of academic leaders with expertise in CNS diseases and the development of novel therapeutics. \u201cWe are pleased to have assembled an accomplished and diverse group of advisors with expertise that spans clinical development in neurology and translational science, as well as CNS disease biology. The advisors\u2019 expertise will be highly valuable for optimizing the development path and therapeutic potential of the company\u2019s &hellip; Continue reading \"Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-25T12:03:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDY2MSMzOTQyNDM5IzIxMjUwMjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards","datePublished":"2021-01-25T12:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/"},"wordCount":791,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDY2MSMzOTQyNDM5IzIxMjUwMjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/","name":"Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDY2MSMzOTQyNDM5IzIxMjUwMjQ=","datePublished":"2021-01-25T12:03:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDY2MSMzOTQyNDM5IzIxMjUwMjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDY2MSMzOTQyNDM5IzIxMjUwMjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclerion-therapeutics-announces-clinical-and-scientific-advisory-boards\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/419956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=419956"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/419956\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=419956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=419956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=419956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}